Search research articles
Contact Us
Filters
Showing results (251-260 of 418) with videos related to
Page
of 42
Sort By:
Molecular Cancer Research : MCR
|
November 3, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Future Oncology (London, England)
|
June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Cancer Discovery
|
April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
David J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Future Oncology (London, England)
|
January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
CA: a Cancer Journal for Clinicians
|
October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Cell Reports
|
June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
Hyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.
Nature Metabolism
|
November 14, 2022
Myeloid-derived itaconate suppresses cytotoxic CD8<sup>+</sup> T cells and promotes tumour growth
Hongyun Zhao, Da Teng, Lifeng Yang, et al.
Page
of 42
Search research articles
Search
Showing results (251-260 of 418) with videos related to
Sort By:
Page
of 42
Molecular Cancer Research : MCR
|
November 3, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Future Oncology (London, England)
|
June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Cancer Discovery
|
April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
David J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.
Future Oncology (London, England)
|
January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
CA: a Cancer Journal for Clinicians
|
October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Cell Reports
|
June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
Hyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.
Nature Metabolism
|
November 14, 2022
Myeloid-derived itaconate suppresses cytotoxic CD8<sup>+</sup> T cells and promotes tumour growth
Hongyun Zhao, Da Teng, Lifeng Yang, et al.
Page
of 42